Share This Page
VARIBAR PUDDING Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Varibar Pudding, and when can generic versions of Varibar Pudding launch?
Varibar Pudding is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in VARIBAR PUDDING is barium sulfate. Two suppliers are listed for this compound. Additional details are available on the barium sulfate profile page.
US Patents and Regulatory Information for VARIBAR PUDDING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | VARIBAR PUDDING | barium sulfate | PASTE;ORAL | 208844-001 | Oct 14, 2016 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Varibar Pudding (barium sulfate for oral suspension) investment fundamentals: exclusivity, IP risk, and commercial outlook
Executive summary: Varibar Pudding is a specialty barium sulfate oral suspension product used in gastrointestinal diagnostic procedures, typically to enhance contrast in imaging. The investment profile is driven less by blockbuster-like drug discovery and more by (1) procedural demand stability, (2) payer and facility purchasing behavior, (3) supply and manufacturing continuity, and (4) the breadth of generic and “authorized” barium sulfate alternatives. For investors, the main risk is pricing power erosion from competitive substitution and entry of lower-cost barium sulfate oral products. The main upside is durable utilization in imaging workflows and the ability to maintain supply reliability and contract positioning.
Because “Varibar Pudding” is a dosage-form specific contrast product, the practical investment decision centers on: where it sits in FDA/Orange Book status, whether it has material formulation or process patents, whether any Paragraph IV or ANDA pathways are relevant, and what other barium sulfate pudding/liquid products compete for the same use.
What is Varibar Pudding, what is it used for, and who buys it?
Featured snippet answer: Varibar Pudding is a barium sulfate oral contrast product used to improve visualization in GI imaging. Buyers are typically hospital radiology departments and outpatient imaging centers, which purchase through GPO contracts, distributor channels, and facility supply procurement.
Mechanism and clinical role
- Barium sulfate is an X-ray contrast agent that improves luminal and mucosal visualization in GI diagnostic workflows.
- “Pudding” denotes a more viscous, spoonable administration format relative to liquid suspensions, which can affect patient tolerance and procedural workflow.
Procurement and revenue drivers
- Sales are commonly driven by:
- Utilization rates of GI imaging procedures (facility volume, protocol preferences).
- Contracting and formulary position within hospital systems.
- Supply continuity and shelf-life performance.
- Switching behavior among comparable barium sulfate oral contrast formats (pudding vs liquid).
What is the FDA regulatory status of Varibar Pudding (Orange Book listing, approvals, and exclusivity)?
Featured snippet answer: Determining Orange Book and exclusivity status is central because it governs how and when FDA-approved generic substitution can occur. For a contrast product like Varibar Pudding, the investment implication is whether it has listed patents that block generic entry.
Regulatory artifacts that matter for investors
- FDA approval type and labeling scope (indication language is less relevant than route, dosage form, and administration instructions).
- Orange Book patent listings tied to:
- Drug substance,
- Drug product formulation,
- Method of use (if any),
- Manufacturing process.
Exclusivity timelines and what they change
- If there are no Orange Book-listed patents or exclusivity is minimal, generic substitution risk is typically earlier and more pronounced.
- If there are meaningful product-process or formulation patents, the risk profile shifts from “generic arrives quickly” to “entry delayed and litigated.”
Investment impact: Contract stability may offset price erosion for a time, but in the absence of durable listed IP, barium sulfate product categories usually face downward pricing pressure once competitors gain parity on supply and label.
What patents protect Varibar Pudding and how broad is the patent estate?
Featured snippet answer: The breadth and enforceability of listed patents (formulation, viscosity modifiers, manufacturing steps, and composition of matter constraints) determines whether generic “pudding” products can be substituted without risk.
Patent estate components to test
-
Composition/formulation patents
- Viscosity control approach
- Suspending agents and stabilizers
- Taste and palatability system (if patented)
- Particle dispersion and re-suspendability controls
-
Manufacturing process patents
- Mixing, granulation, sterilization (if relevant), filling controls
- Particle size management during production
- Stability and shelf-life manufacturing constraints
-
Method-of-use patents
- Less common for established contrast agents unless a specific imaging protocol, sequence, or patient preparation workflow is claimed.
How to gauge strength for investment
-
Strong estates typically have:
- Broad claims that are hard to design around,
- Multiple jurisdictions listed,
- Long tails with active maintenance,
- Litigation history or prosecution record supportive of claim scope.
-
Weak estates typically have:
- Narrow claims easily redesigned,
- Limited or non-influential patent listings relative to the FDA product,
- Off-target claims that do not map onto generic processes.
Investment impact: For a contrast product, design-around feasibility is usually high unless formulation/process is tightly claimed and tied to the FDA product characteristics.
When does Varibar Pudding lose exclusivity and what generic entry risks exist?
Featured snippet answer: Exclusivity loss is the inflection point for substitution risk. The key question is whether any Orange Book-listed patents remain enforceable through the relevant launch window.
Generic entry scenario framework
-
Scenario A: No meaningful listed patents
- Generic entry risk is driven by regulatory and manufacturing capability rather than litigation.
- Competitive entry tends to compress margins quickly.
-
Scenario B: Formulation/process patents listed
- Generic entry may proceed with design-around strategies or face litigation.
- Timing depends on whether patents are enforced and whether claims cover essential product characteristics.
-
Scenario C: Method-of-use patents
- If the labeling ties closely to an imaging protocol that a generic would not infringe, entry could still occur with limited risk.
- If protocol claims are enforceable and the generic label tracks the protected method, litigation increases.
Investment impact: A pure barium sulfate category often sees earlier commoditization unless a specific “pudding” formulation is strongly protected and operationally required.
Have there been any ANDA or Paragraph IV challenges for Varibar Pudding?
Featured snippet answer: Paragraph IV relevance depends on Orange Book listings. If patents are listed for the product, generic sponsors may file ANDAs with Paragraph IV certifications, triggering litigation and potential settlement.
What investors should map
- Whether any ANDA(s) reference Varibar Pudding.
- Whether there are Paragraph IV notices and court outcomes.
- Whether settlements create delayed launch dates or “carve-out” designs.
Why this matters commercially
- A settlement can create a temporary “protected” window even if a broader patent estate is weak.
- Conversely, absence of Paragraph IV activity suggests either weak patent protection or the market is not attractive enough for challengers.
What patent litigation affects Varibar Pudding and what are likely settlement outcomes?
Featured snippet answer: Litigation drives entry timing more than “paper” patent strength. Settlements in contrast products often involve delayed launch, design-around requirements, or label carve-outs.
Litigation signals investors track
- Court filings that establish claim construction and infringement theories.
- Whether the defendant targets specific claim limitations (often the best indicator of design-around feasibility).
- Settlement terms that specify:
- Effective date for launch,
- Required formulation changes,
- Labeling limitations,
- Supply chain or exclusivity restrictions.
Commercial consequence
- Litigation that narrows enforceable scope can lead to earlier generic entry with revised formulations.
- Litigation that upholds broad claims can sustain pricing and contract share longer.
How does Varibar Pudding compare with other barium sulfate oral contrast products (pudding vs liquid)?
Featured snippet answer: Varibar Pudding competes on administration format and facility workflow, not on therapeutic novelty. Substitution with other barium sulfate oral suspensions is feasible if the alternative meets imaging protocols and patient handling requirements.
Comparison dimensions
- Viscosity and spoonability versus pourable suspension
- Re-suspendability and preparation time
- Patient tolerability profile (nausea, choking risk considerations)
- Storage stability and shelf-life
- Supply reliability and lot-to-lot consistency
- Label instructions and compatibility with existing facility protocols
Investment implication
- The more protocols accept multiple barium sulfate formats, the faster the price compression once a lower-cost competitor enters.
Which companies produce competing barium sulfate pudding or oral suspensions, and how intense is the competitive landscape?
Featured snippet answer: Competition is typically concentrated among manufacturers of radiology contrast liquids and oral suspensions, with “pudding” formats often produced by a smaller set of specialty manufacturers. Competitive intensity depends on number of interchangeable SKUs available through distributors and GPO contracts.
What to evaluate in competitor mapping
- Number of alternative FDA-approved oral contrast products matching viscosity/route constraints.
- Distributor availability and contracting terms.
- Product availability during shortages (supply continuity is a competitive weapon).
- Any unique patient handling benefits that procurement committees prioritize.
What formulation and manufacturing IP barriers could block generic or authorized alternatives?
Featured snippet answer: For “pudding” contrast, manufacturing and formulation constraints are the main barriers. Claims around stabilizers, particle dispersion, and shelf-life stability are the most likely to be materially limiting.
Key technical/IP pressure points
- Stabilizer systems that maintain suspension uniformity
- Particle size distribution and re-dispersion controls
- Viscosity targets that match clinical handling and imaging needs
- Packaging and fill-finish parameters that protect stability through shelf life
Commercial translation
- If process is hard to reproduce at scale with stable viscosity and re-suspendability, generic entry can be delayed by validation time.
- If the process is straightforward, cost-based competition dominates quickly.
What is the business model and revenue exposure profile for Varibar Pudding?
Featured snippet answer: Revenue is exposed to imaging utilization and procurement contracting cycles, with additional sensitivity to supply events and competitor price actions.
Fundamental drivers
- Demand: GI imaging volumes and facility case-mix mix.
- Channel: GPO and distributor volumes, contract duration, and tenders.
- Price: SKU-specific pricing power versus substitution options.
- Supply: manufacturing uptime, raw material sourcing, and QA release speed.
- Regulatory operations: batch release and labeling compliance costs.
Key risk for investors
- If multiple equivalent barium sulfate products satisfy protocols, procurement may switch based on price and availability.
How strong is the patent estate for Varibar Pudding versus the likely commoditization curve?
Featured snippet answer: The patent estate strength determines whether Varibar Pudding remains differentiated on price and contract positioning. In barium sulfate contrast categories, differentiation often erodes quickly unless formulation/process is meaningfully protected and operationally required.
Investment-grade scoring rubric
- Patent coverage breadth tied to the exact FDA product characteristics.
- Claim enforceability based on file history and claim construction.
- Evidence of design-around difficulty from prior generic attempts or litigation.
- Duration of listed patents overlapping the commercial horizon.
Decision logic
- Weak or design-aroundable IP usually produces a steep commoditization curve.
- Strong, product-tied IP sustains margins and can justify premium valuation assumptions.
Key Takeaways
- Varibar Pudding is a specialty radiology contrast product where investment fundamentals depend on procurement behavior, imaging utilization, and supply continuity more than therapeutic innovation.
- The critical diligence point is the FDA and Orange Book patent landscape: listed patents and exclusivity timelines drive generic and authorized-alternative entry risk.
- For barium sulfate “pudding” formats, formulation and manufacturing process constraints are the main IP barriers; if they are narrow or design-aroundable, pricing pressure follows quickly.
- Competitive intensity is typically substitution-driven across barium sulfate oral suspensions. Without durable, product-specific patent protection, margin compression is the dominant commercial risk.
- A credible investment view requires mapping (1) patent expirations, (2) any Paragraph IV challenges, and (3) litigation/settlement-driven launch calendars.
FAQs
- How does Orange Book listing status determine whether generics can launch for Varibar Pudding?
- What specific formulation elements in barium sulfate pudding are most likely to be claimed and difficult to design around?
- Do hospitals typically substitute barium sulfate pudding products based on price, or do protocols lock in a specific format?
- How do supply shortages in contrast agents affect facility purchasing and long-term contract retention?
- What settlement terms in contrast-product patent cases most strongly influence generic launch timing?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drug Approval and Databases: Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
More… ↓
